A comparative study of the effectiveness of Pfizer-BioNTech (BNT162b2), Astra Zeneca (ChAdOx1nCoV-19) and Sinopharm (BBIBP-CorV) vaccines in eliciting Humoral immunity in a sample of vaccinated population from Iraq.
DOI:
https://doi.org/10.3329/bjms.v22i3.65323Keywords:
effectiveness; humoral immunity; Pfizer; Sinopharm; Astra ZenecaAbstract
Background: In order to tackle COVID-19 pandemic and the emerging variants, researchers around the globe have investigated many vaccine candidates from different manufacturers, however vaccine development is not an easy task but is a top priority to restore normalcy as represented a step to achieve the desired herd immunity threshold.
Patients and methods: in this study we assessed and compared the level of IgG anti-RBD neutralizing antibodies triggered from each vaccine against SARS-CoV2 infection in 123 vaccinated subjects, by using isotypeand species- free competitive blocking ELISA. Blood samples were taken from vaccinated individuals 1 and 8 months after the second dose of the vaccines.
Results: the findings of the current study revealed that two-dose vaccination might be effective to trigger robust humoral neutralizing immunity at 1month and even durable for as long as 8months with different sustained levels among the three studied previously mentioned vaccines. The serum level of the neutralizing IgG antibodies, Pfizer group revealed the highest level compared to AstraZeneca and Sinopharm groups (P<0.05); the Sinopharm showed trend of higher levels of neutralizing antibodies than AstraZeneca but without reaching statistical significance (P>0.05). Additionally, the serum level of neutralizing IgG antibodies, which represent the humeral immunity to SARSCoV- 2, was shown to be far higher in 1-month than in 8-month post-2nd dose vaccination groups (P<0.0001).
Conclusion: Altogether, it is concluded that Pfizer vaccine proved to be of highest and most durable neutralizing anti-RBD IgG antibodies and followed with Sinopharm and AstraZeneca vaccines.
Bangladesh Journal of Medical Science Vol. 22 No. 03 July’23 Page : 553-563
Downloads
3
2
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Furqan Mohammed, Ahmed Sahib
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in the Bangladesh Journal of Medical Science agree to the following terms that:
- Authors retain copyright and grant Bangladesh Journal of Medical Science the right of first publication of the work.
Articles in Bangladesh Journal of Medical Science are licensed under a Creative Commons Attribution 4.0 International License CC BY-4.0.This license permits use, distribution and reproduction in any medium, provided the original work is properly cited.- Authors are able to enter into separate, additional contractual arrangements for the distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted to post their work online (e.g., in institutional repositories or on their website) as it can lead to productive exchanges, as well as greater citation of published work.
